IFRX קפיטליזציה חשבונאית InflaRx NV

InflaRx N.V. (IFRX) attracts top immunologists through its research into the complement system, retaining talent with high salaries and equity. The company's German laboratories develop cutting-edge antibodies for inflammation therapy, leveraging its own patent portfolio. The market trend visualized in monetary terms, which stands at 0.17, complements data on the advancement of drug pipelines via US distributors without engaging in merger and acquisition deals.

The long-term reliability of InflaRx N.V. (IFRX) is determined by the difference between all assets and liabilities, which allows the firm's book capitalization history to filter out speculative noise from the actual value of its property. The growth of this indicator confirms the actual accumulation of capital, which in the case of InflaRx N.V. is supported by high sales margins and the optimization of biologic supply chains to global medical centers.